Cyclophosphamide as a first-line therapy in LGL leukemia

被引：80

作者：

Moignet, A. ^{[1
]}

Hasanali, Z. ^{[2
]}

Zambello, R. ^{[3
]}

Pavan, L. ^{[3
]}

Bareau, B. ^{[4
]}

Tournilhac, O. ^{[5
]}

Roussel, M. ^{[6
]}

Fest, T. ^{[6
,8
]}

Awwad, A. ^{[2
]}

Baab, K. ^{[2
]}

Semenzato, G. ^{[3
]}

Houot, R. ^{[1
,7
,8
]}

Loughran, T. P., Jr. ^{[2
]}

Lamy, T. ^{[1
,7
,8
]}

机构：

[1] Rennes Univ Hosp, Dept Clin Hematol, Rennes, France

[2] Penn State Coll Med, Penn State Hershey Canc Inst, Hershey, PA USA

[3] Univ Padua, Sch Med, Dept Med, Hematol & Clin Immunol Branch, Padua, Italy

[4] Clin Cesson Sevigne Rennes, Rennes, France

[5] Hop Estaing, Dept Clin Hematol, Clermont Ferrand, France

[6] Rennes Univ Hosp, Hematol Immunol & Cell Therapy Dept, Rennes, France

[7] INSERM, CIC 0203, F-75654 Paris 13, France

[8] Univ Rennes 1, Rennes, France

来源：

LEUKEMIA | 2014年 / 28卷 / 05期

关键词：

GRANULAR LYMPHOCYTE LEUKEMIA; RED-CELL APLASIA; STAT3; MUTATIONS; LYMPHOPROLIFERATIVE DISEASE; COHORT;

D O I：

10.1038/leu.2013.359

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1134 / 1136

页数：4

共 50 条

[21] First-line therapy for chronic myeloid leukemia: past, present, and future
Pavlovsky, Carolina
Kantarjian, Hagop
Cortes, Jorge E.
AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (05) : 287 - 293
[22] Optimal First-Line Therapy for Previously Untreated Chronic Lymphocytic Leukemia
Brown, Jennifer R.
ONCOLOGY-NEW YORK, 2015, 29 (06): : 442 - +
[23] First-line Therapy for Chronic Myeloid Leukemia: New Horizons and an Update
Saglio, Giuseppe
Baccarani, Michele
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (03): : 169 - 176
[24] Introduction of Imatinib as First-line Therapy for Chronic Myeloid Leukemia in Cuba
Pavon, Valia
Gomez, Rafael
Jaime, Juan C.
Hernandez, Porfirio
Arencibia, Alberto
Espinosa-Martinez, Edgardo
Avila, Onel M.
Hernandez, Carlos
Gonzalez, Alejandro
Carnot, Jose
Espinosa-Estrada, Edgardo
Lam, Rosa M.
Amor, Ana M.
Lavauth, Kalia
Hernandez, Annia
MEDICC REVIEW, 2011, 13 (01) : 36 - 41
[25] Medical decision analysis for first-line therapy of chronic myeloid leukemia
Rochau, Ursula
Sroczynski, Gaby
Wolf, Dominik
Schmidt, Stefan
Conrads-Frank, Annette
Jahn, Beate
Saverno, Kim
Brixner, Diana
Radich, Jerald
Gastl, Guenther
Siebert, Uwe
LEUKEMIA & LYMPHOMA, 2014, 55 (08) : 1758 - 1767
[26] Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia
Abrisqueta, Pau
Villamor, Neus
Jose Terol, Maria
Gonzalez-Barca, Eva
Gonzalez, Marcos
Ferra, Christelle
Abella, Eugenia
Delgado, Julio
Garcia-Marco, Jose A.
Gonzalez, Yolanda
Carbonell, Felix
Ferrer, Secundino
Monzo, Encarna
Jarque, Isidro
Muntanola, Ana
Constants, Mireia
Escoda, Lourdes
Calvo, Xavier
Bobillo, Sabela
Bruno Montoro, Jose
Montserrat, Emili
Bosch, Francesc
BLOOD, 2013, 122 (24) : 3951 - 3959
[27] Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis?
Hogan, Jonathan
Schwenk, Michael H.
Radhakrishnan, Jai
KIDNEY INTERNATIONAL, 2012, 82 (12) : 1256 - 1260
[28] First-line therapy for hypertension
Eledrisi, Mohsen S.
ANNALS OF INTERNAL MEDICINE, 2007, 146 (08) : 615 - 615
[29] Lenacapavir in first-line therapy
Orkin, Chloe
LANCET HIV, 2023, 10 (01): : E2 - E3
[30] Lamivudine: is it first-line therapy?
Dienstag, JL
ANTIVIRAL THERAPY, 2002, 7 (04) : L83 - L83

← 1 2 3 4 5 →